Concepedia

Amy L. Cummings

AL

15

Publications

1.1K

Citations

12

H-Index

2013

Active since

Affiliations

University of California, Los Angeles(Current)

University of California San Diego

Tennessee Oncology

Columbia University

Institut Gustave Roussy

Amy L. Cummings is an author at University of California, Los Angeles specializing in medicine, oncology, and immunotherapy.

ORCID

Top concepts

Publications per year

2013–2024

15

Publications

15

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Aaron Lisberg, Amy L. Cummings, Jonathan W. Goldman et al. · Journal of Thoracic Oncology · 2018 · 577 citations · Full text

, , +7

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti et al. · Cancer Discovery · 2023 · 166 citations · Full text

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong et al. · Nature · 2024 · 117 citations · Full text

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer

Siwen Hu‐Lieskovan, Aaron Lisberg, Jesse M. Zaretsky et al. · Clinical Cancer Research · 2019 · 68 citations · Full text

Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44

Amy L. Cummings, Jaklin Gukasyan, Henry Y. Lu et al. · Nature Cancer · 2020 · 47 citations · Full text

, , +8

Rows per page

1–5 of 15